Back
 JDM  Vol.6 No.4 , November 2016
Host Factors Alter Effects of Angiopoietin-Like Protein 8 on Glucose Homeostasis in Diabetic Mice
Abstract: Recovery of functional beta cell mass offers a biological cure for type 1 diabetes. However, beta cell mass is difficult to regain once lost since the proliferation rate of beta cells after youth is very low. Angiopoietin like-protein 8 (ANGPTL8), a peptide that has a role in the regulation of lipoprotein lipase activity, was reported to increase beta cell proliferation in mice in 2013. Subsequent studies of human ANGPTL8 for short term (3 to 8 days) in non-diabetic mice showed little or no increase in beta cell proliferation. Here, we examined the effect of ANGPTL8 on glucose homeostasis in models that have not been examined previously. We expressed mouse ANGPTL8 using adenovirus in 2 mouse models of diabetes (streptozotocin and Non-Obese Diabetic (NOD) mice) over 2 weeks. Also, we tested ANGPTL8 in NOD mice deficient in leukocyte 12-lipoxygenase (12LO), an enzyme that contributes to insulitis and loss of beta cell function in NOD, in an effort to determine whether 12LO deficiency alters the response to ANGPTL8. Adenovirus-mediated expression of ANGPTL8 lowered blood glucose levels in streptozotocin treated mice without an increase in beta cell proliferation or serum insulin concentration. While ANGPTL8 did not reverse hyperglycemia in overtly hyperglycemic NOD mice or alter glucose homeostasis of non-diabetic NOD mice, ANGPTL8 reduced blood glucose levels in 12LOKO NOD mice. However, the lower glucose levels in 12LOKO NOD were not associated with higher serum insulin levels or beta cell proliferation. In summary, while mouse ANGPTL8 does not increase beta cell proliferation in NOD mice or streptozotocin treated mice in agreement with studies in non-diabetic mice, it lowers blood glucose levels in multiple low-dose streptozotocin induced diabetes and 12LO deficiency indicating that host factors influence the impact of ANGPTL8 on glucose homeostasis.
Cite this paper: Liu, S. , Smith, E. , King, T. , Glenn, L. , Trevino, M. , Park, S. , Machida, Y. , Villaflor, C. , Grzesik, W. , Morris, M. , Imai, Y. , Nadler, J. (2016) Host Factors Alter Effects of Angiopoietin-Like Protein 8 on Glucose Homeostasis in Diabetic Mice. Journal of Diabetes Mellitus, 6, 277-290. doi: 10.4236/jdm.2016.64029.
References

[1]   Atkinson, M.A. and Ogle, G.D. (2013) Improving Diabetes Care in Resource-Poor Countries: Challenges and Opportunities. The Lancet Diabetes & Endocrinology, 1, 268-270.
http://dx.doi.org/10.1016/S2213-8587(13)70172-4

[2]   Kushner, J.A. (2013) The Role of Aging upon Beta Cell Turnover. Journal of Clinical Investigation, 123, 990-995.
http://dx.doi.org/10.1172/JCI64095

[3]   Yi, P., Park, J.S. and Melton, D.A. (2013) Betatrophin: A Hormone That Controls Pancreatic Beta Cell Proliferation. Cell, 153, 747-758.
http://dx.doi.org/10.1016/j.cell.2013.04.008

[4]   Chen, J., et al. (2015) In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats. Diabetologia, 58, 1036-1044.
http://dx.doi.org/10.1007/s00125-015-3521-z

[5]   Cox, A.R., et al. (2016) Resolving Discrepant Findings on ANGPTL8 in Beta-Cell Proliferation: A Collaborative Approach to Resolving the Betatrophin Controversy. PLoS ONE, 11, e0159276.
http://dx.doi.org/10.1371/journal.pone.0159276

[6]   Cox, A.R., et al. (2015) Angiopoietin-Like Protein 8 (ANGPTL8)/Betatrophin Overexpression Does Not Increase Beta Cell Proliferation in Mice. Diabetologia, 58, 1523-1531.
http://dx.doi.org/10.1007/s00125-015-3590-z

[7]   Yi, P., Park, J.S. and Melton, D.A. (2014) Perspectives on the Activities of ANGPTL8/Betatrophin. Cell, 159, 467-468.
http://dx.doi.org/10.1016/j.cell.2014.09.028

[8]   Gusarova, V., et al. (2014) ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion. Cell, 159, 691-696.
http://dx.doi.org/10.1016/j.cell.2014.09.027

[9]   Fu, Z., Abou-Samra, A.B. and Zhang, R. (2015) A Lipasin/Angptl8 Monoclonal Antibody Lowers Mouse Serum Triglycerides Involving Increased Postprandial Activity of the Cardiac Lipoprotein Lipase. Scientific Reports, 5, 18502.
http://dx.doi.org/10.1038/srep18502

[10]   Quagliarini, F., et al. (2012) Atypical Angiopoietin-Like Protein That Regulates ANGPTL3. Proceedings of the National Academy of Sciences of the United States of America, 109, 19751-19756.
http://dx.doi.org/10.1073/pnas.1217552109

[11]   Wang, Y., et al. (2013) Mice lacking ANGPTL8 (Betatrophin) Manifest Disrupted Triglyceride Metabolism without Impaired Glucose Homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 110, 16109-16114.
http://dx.doi.org/10.1073/pnas.1315292110

[12]   Hanson, R.L., et al. (2016) The Arg59Trp Variant in ANGPTL8 (betatrophin) Is Associated with Total and HDL-Cholesterol in American Indians and Mexican Americans and Differentially Affects Cleavage of ANGPTL3. Molecular Genetics and Metabolism, 118, 128-137.
http://dx.doi.org/10.1016/j.ymgme.2016.04.007

[13]   Peloso, G.M., et al. (2014) Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks. The American Journal of Human Genetics, 94, 223-232.
http://dx.doi.org/10.1016/j.ajhg.2014.01.009

[14]   Green-Mitchell, S.M., et al. (2013) Deletion of 12/15-Lipoxygenase Alters Macrophage and Islet Function in NOD-Alox15(Null) Mice, Leading to Protection against Type 1 Diabetes Development. PLoS ONE, 8, e56763.
http://dx.doi.org/10.1371/journal.pone.0056763

[15]   McDuffie, M., et al. (2008) Nonobese Diabetic (NOD) Mice Congenic for a Targeted Deletion of 12/15-Lipoxygenase Are Protected from Autoimmune Diabetes. Diabetes, 57, 199-208.
http://dx.doi.org/10.2337/db07-0830

[16]   Imai, Y., et al. (2007) Reduction of Hepatosteatosis and Lipid Levels by an Adipose Differentiation-Related Protein Antisense Oligonucleotide. Gastroenterology, 132, 1947-1954.
http://dx.doi.org/10.1053/j.gastro.2007.02.046

[17]   Kulkarni, R.N., Mizrachi, E.-B., Ocana, A.G. and Stewart, A.F. (2012) Human Beta-Cell Proliferation and Intracellular Signaling: Driving in the Dark without a Road Map. Diabetes, 61, 2205-2213.
http://dx.doi.org/10.2337/db12-0018

[18]   Jiao, Y., Le Lay, J., Yu, M., Naji, A. and Kaestner, K.H. (2014) Elevated Mouse Hepatic Betatrophin Expression Does Not Increase Human Beta-Cell Replication in the Transplant Setting. Diabetes, 63, 1283-1288.
http://dx.doi.org/10.2337/db13-1435

[19]   Shen, W., et al. (2015) Inhibition of DYRK1A and GSK3B Induces Human Beta-Cell Proliferation. Nature Communications, 6, Article Number: 8372.
http://dx.doi.org/10.1038/ncomms9372

[20]   Wang, P., et al. (2015) A High-Throughput Chemical Screen Reveals That Harmine-Mediated Inhibition of DYRK1A Increases Human Pancreatic Beta Cell Replication. Nature Medicine, 21, 383-388.
http://dx.doi.org/10.1038/nm.3820

[21]   Dirice, E., et al. (2016) Inhibition of DYRK1A Stimulates Human Beta-Cell Proliferation. Diabetes, 65, 1660-1671.
http://dx.doi.org/10.2337/db15-1127

[22]   El Ouaamari, A., et al. (2016) SerpinB1 Promotes Pancreatic Beta Cell Proliferation. Cell Metabolism, 23, 194-205.
http://dx.doi.org/10.1016/j.cmet.2015.12.001

[23]   Imai, Y., et al. (2013) Interaction between Cytokines and Inflammatory Cells in Islet Dysfunction, Insulin Resistance and Vascular Disease. Diabetes Obesity & Metabolism, 15, 117-129.
http://dx.doi.org/10.1111/dom.12161

[24]   Morris, D.L. (2015) Minireview: Emerging Concepts in Islet Macrophage Biology in Type 2 Diabetes. Molecular Endocrinology, 29, 946-962.
http://dx.doi.org/10.1210/me.2014-1393

[25]   Sell, H., Habich, C. and Eckel, J. (2012) Adaptive Immunity in Obesity and Insulin Resistance. Nature Reviews Endocrinology, 8, 709-716.
http://dx.doi.org/10.1038/nrendo.2012.114

 
 
Top